- Home
- BLNK vs RIGL Comparison
BLNK vs RIGL Comparison
Compare BLNK & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLNK | RIGL |
|---|---|---|
| Founded | 2009 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.3M | 537.6M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | BLNK | RIGL |
|---|---|---|
| Price | $0.76 | $43.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $2.13 | ★ $43.20 |
| AVG Volume (30 Days) | ★ 7.1M | 562.5K |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2698.26 |
| EPS | N/A | ★ 6.20 |
| Revenue | $106,631,000.00 | ★ $282,076,000.00 |
| Revenue This Year | N/A | $65.53 |
| Revenue Next Year | $17.87 | $0.22 |
| P/E Ratio | ★ N/A | $6.71 |
| Revenue Growth | N/A | ★ 79.13 |
| 52 Week Low | $0.63 | $14.63 |
| 52 Week High | $2.65 | $52.24 |
Technical Indicators
Market Signals| Indicator | BLNK | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 25.91 | 54.78 |
| Support Level | $0.77 | $40.52 |
| Resistance Level | $0.85 | $43.58 |
| Average True Range (ATR) | 0.09 | 2.59 |
| MACD | -0.02 | -0.65 |
| Stochastic Oscillator | 0.00 | 44.02 |
Price Performance
Historical ComparisonAbout BLNK Blink Charging Co.
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.